A Reuters report on Friday revealed that FDA researchers have found additional molecular evidence tying blockbuster asthma ...

(NASDAQ:GPCR) stands against the other NASDAQ stocks ... The drug was designed through the company’s structure-based drug ...

Septerna, Inc. ( (SEPN) ) has released its Q3 earnings. Here is a breakdown of the information Septerna, Inc. presented to ...

A three-decade series of coincidences will likely help doctors treat narcolepsy — and possibly prevent opioid addiction — and ...

Georgios Skiniotis, PhD, to develop and lead new center focusing on advanced imaging techniques, including cryo-ET.

The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor ...

The hypoparathyroidism treatment space has made a buzz in 2024 with a major drug approval, acquisitions, and big advances in ...

Deep Pipeline of GPCR Programs Focused Initially on Indications in Endocrinology, Immunology and Inflammation, and Metabolic Diseases Phase 1 Clinical Trial Ongoing for SEP-786, Oral Small Molecule ...

Deep Pipeline of GPCR Programs Focused Initially on Indications in Endocrinology, Immunology and Inflammation, and Metabolic Diseases Phase 1 Clinical Trial Ongoing for SEP-786, Oral Small Molecule ...

Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) – Investment analysts at Lifesci Capital boosted their FY2024 EPS ...

Vasoactive Intestinal Peptide (VIP) is an intriguing neuropeptide with a wide range of potential biological impacts, primarily hypothesized in tissues, cells, and internal systems. Since its discovery ...

(Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced the ...